Summary#
This bill would change a rule in the Public Health Service Act so federally-qualified health centers (FQHCs) must get the 340B discounted price when they buy outpatient drugs. The main change is a ban on agreements that let manufacturers charge more than the 340B ceiling price at purchase and then fix the difference later by rebates or reimbursements. The broad goal is to make sure FQHCs pay the discounted price up front.
- Main change: The Secretary of Health and Human Services may not agree to any manufacturer arrangement that requires a covered entity that is an FQHC to pay more than the 340B ceiling price at the time of purchase.
- No after-the-fact reconciliation: The bill says such arrangements that charge more at purchase and later reconcile by rebate, reimbursement, or other payment are not allowed.
- Effective immediately: The change would apply to drugs bought on or after the date the law starts.
- Applies to existing agreements for review: From enactment, the change must be considered when deciding whether existing manufacturer agreements meet 340B requirements.
What it means for you#
- Federally-qualified health centers (FQHCs): Must be charged no more than the 340B ceiling price when they buy covered outpatient drugs. They would not have to wait for rebates or later payments to get the full discount.
- Drug manufacturers: Could not require FQHCs to pay above the 340B ceiling price at purchase and then recover the difference later. They would need to change contracts and billing practices that currently use later reconciliation.
- Covered entities generally: The bill names FQHCs specifically. It requires the Secretary to refuse arrangements that let those entities pay more at purchase with later rebates.
- Patients and pharmacies: The bill does not directly change patient coverage rules or pharmacy licensing. Any effects on patients or pharmacies would be indirect and are not spelled out in the bill.
- Federal agencies: The Secretary of Health and Human Services must treat the new rule when reviewing whether agreements comply with the 340B program.
Expenses#
No publicly available information.
- The bill text does not include a fiscal estimate or cost figures.
- Possible administrative and compliance costs could fall on manufacturers and on FQHCs as contracts and purchase systems are changed. (This is an inferred possibility, not a stated cost in the bill.)
- The bill does not state enforcement costs or whether additional staff or systems at HHS would be needed to monitor compliance.
- The bill does not say if there would be savings for FQHCs or losses for manufacturers; no dollar amounts are provided.
Proponents' View#
- The bill appears intended to make sure FQHCs receive the 340B discount right away at purchase.
- Supporters may argue this prevents delays and cash-flow problems for health centers that otherwise would pay higher prices up front and wait for later rebates.
- This could be seen as strengthening the practical protection of the 340B discount for the named covered entities.
Opponents' View#
- One concern is that the bill does not explain how enforcement would work or what penalties apply if a manufacturer or purchaser violates the rule.
- The bill does not clearly say how it affects existing complex arrangements, such as purchases routed through pharmacies or third parties.
- This could create legal and administrative disputes while contracts are renegotiated.
- It is unclear whether manufacturers would change pricing, limit supply, or alter distribution practices to respond to the rule; the bill does not address those possible effects.